vs
Side-by-side financial comparison of GSI TECHNOLOGY INC (GSIT) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
GSI TECHNOLOGY INC is the larger business by last-quarter revenue ($6.1M vs $5.5M, roughly 1.1× Taysha Gene Therapies, Inc.). GSI TECHNOLOGY INC runs the higher net margin — -49.7% vs -507.8%, a 458.1% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 12.2%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 8.6%).
Triad GSI is an American voting machine vendor based in Xenia, Ohio. Their main products are election-related computer hardware and software for counting ballots, as well as voter registration.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
GSIT vs TSHA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.1M | $5.5M |
| Net Profit | $-3.0M | $-27.9M |
| Gross Margin | 52.7% | — |
| Operating Margin | -113.7% | -516.0% |
| Net Margin | -49.7% | -507.8% |
| Revenue YoY | 12.2% | 171.3% |
| Net Profit YoY | 25.0% | -48.3% |
| EPS (diluted) | $-0.09 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.1M | $5.5M | ||
| Q3 25 | $6.4M | $0 | ||
| Q2 25 | $6.3M | $2.0M | ||
| Q1 25 | $5.9M | $2.3M | ||
| Q4 24 | $5.4M | $2.0M | ||
| Q3 24 | $4.5M | $1.8M | ||
| Q2 24 | $4.7M | $1.1M | ||
| Q1 24 | $5.2M | $3.4M |
| Q4 25 | $-3.0M | $-27.9M | ||
| Q3 25 | $-3.2M | $-32.7M | ||
| Q2 25 | $-2.2M | $-26.9M | ||
| Q1 25 | $-2.2M | $-21.5M | ||
| Q4 24 | $-4.0M | $-18.8M | ||
| Q3 24 | $-5.5M | $-25.5M | ||
| Q2 24 | $1.1M | $-20.9M | ||
| Q1 24 | $-4.3M | $-24.1M |
| Q4 25 | 52.7% | — | ||
| Q3 25 | 54.8% | — | ||
| Q2 25 | 58.1% | — | ||
| Q1 25 | 56.1% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 38.6% | — | ||
| Q2 24 | 46.3% | — | ||
| Q1 24 | 51.6% | — |
| Q4 25 | -113.7% | -516.0% | ||
| Q3 25 | -49.5% | — | ||
| Q2 25 | -34.6% | -1347.1% | ||
| Q1 25 | -38.7% | -930.5% | ||
| Q4 24 | -74.9% | -985.8% | ||
| Q3 24 | -122.7% | -1448.4% | ||
| Q2 24 | 23.1% | -1915.4% | ||
| Q1 24 | -87.6% | -713.3% |
| Q4 25 | -49.7% | -507.8% | ||
| Q3 25 | -49.4% | — | ||
| Q2 25 | -35.3% | -1353.6% | ||
| Q1 25 | -37.9% | -935.2% | ||
| Q4 24 | -74.4% | -929.0% | ||
| Q3 24 | -120.0% | -1427.5% | ||
| Q2 24 | 23.1% | -1882.0% | ||
| Q1 24 | -83.9% | -705.4% |
| Q4 25 | $-0.09 | $-0.08 | ||
| Q3 25 | $-0.11 | $-0.09 | ||
| Q2 25 | $-0.08 | $-0.09 | ||
| Q1 25 | $-0.09 | $-0.08 | ||
| Q4 24 | $-0.16 | $-0.07 | ||
| Q3 24 | $-0.21 | $-0.10 | ||
| Q2 24 | $0.04 | $-0.09 | ||
| Q1 24 | $-0.17 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $70.7M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $83.6M | $246.9M |
| Total Assets | $98.5M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.7M | $319.8M | ||
| Q3 25 | $25.3M | $297.3M | ||
| Q2 25 | $22.7M | $312.8M | ||
| Q1 25 | $13.4M | $116.6M | ||
| Q4 24 | $15.1M | $139.0M | ||
| Q3 24 | $18.4M | $157.7M | ||
| Q2 24 | $21.8M | $172.7M | ||
| Q1 24 | $14.4M | $124.0M |
| Q4 25 | $83.6M | $246.9M | ||
| Q3 25 | $38.6M | $219.0M | ||
| Q2 25 | $37.4M | $248.7M | ||
| Q1 25 | $28.2M | $55.1M | ||
| Q4 24 | $29.9M | $71.5M | ||
| Q3 24 | $33.3M | $88.8M | ||
| Q2 24 | $38.0M | $108.9M | ||
| Q1 24 | $36.0M | $53.8M |
| Q4 25 | $98.5M | $343.3M | ||
| Q3 25 | $52.0M | $316.6M | ||
| Q2 25 | $50.5M | $333.3M | ||
| Q1 25 | $43.3M | $138.4M | ||
| Q4 24 | $44.1M | $160.4M | ||
| Q3 24 | $47.4M | $180.2M | ||
| Q2 24 | $52.3M | $200.4M | ||
| Q1 24 | $42.5M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.9M | $-26.7M |
| Free Cash FlowOCF − Capex | $-8.2M | — |
| FCF MarginFCF / Revenue | -134.4% | — |
| Capex IntensityCapex / Revenue | 4.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.9M | $-26.7M | ||
| Q3 25 | $-887.0K | $-24.2M | ||
| Q2 25 | $-1.7M | $-20.2M | ||
| Q1 25 | $-1.7M | $-22.0M | ||
| Q4 24 | $-3.6M | $-18.3M | ||
| Q3 24 | $-3.5M | $-21.6M | ||
| Q2 24 | $-4.3M | $-21.5M | ||
| Q1 24 | $-7.1M | $-19.8M |
| Q4 25 | $-8.2M | — | ||
| Q3 25 | $-906.0K | $-24.3M | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-3.6M | $-18.3M | ||
| Q3 24 | $-3.5M | $-21.6M | ||
| Q2 24 | $-4.3M | $-21.7M | ||
| Q1 24 | $-7.2M | $-19.9M |
| Q4 25 | -134.4% | — | ||
| Q3 25 | -14.1% | — | ||
| Q2 25 | -27.6% | — | ||
| Q1 25 | -28.3% | — | ||
| Q4 24 | -66.1% | -905.5% | ||
| Q3 24 | -76.6% | -1210.9% | ||
| Q2 24 | -92.0% | -1951.9% | ||
| Q1 24 | -139.0% | -584.5% |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.1% | 0.1% | ||
| Q3 24 | 0.1% | 2.0% | ||
| Q2 24 | 0.7% | 18.1% | ||
| Q1 24 | 0.2% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.96× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GSIT
| Distribution | $5.6M | 92% |
| Other | $459.0K | 8% |
TSHA
Segment breakdown not available.
